Journal
EXPERIMENTAL NEUROLOGY
Volume 224, Issue 1, Pages 66-73Publisher
ACADEMIC PRESS INC ELSEVIER SCIENCE
DOI: 10.1016/j.expneurol.2010.03.024
Keywords
-
Categories
Funding
- CIBERNED [CB06/05/1109]
- Ministerio de Ciencia e Innovacion Tecnologica [SAF 2007/61565]
- Fondo de Investigaciones Sanitarias (FIS) [PS09/01900]
- Comunidad de Madrid [S-SAL/0261/2006]
- Spanish Ministry of Science (MICINN)
Ask authors/readers for more resources
The endocannabinoid system may be the target of novel therapies in a wide variety of diseases. Among them, those related with amyloid accumulation will be discussed in the present review. Several components of this system (CB1 and CB2 receptors, endocannabinoids, FAAH enzyme) may participate in different aspects of amyloid pathophysiology such as, for instance, synaptic activity, cell migration, cytokine production or phagocytic activity. Consistent with recent data, putative lines of research and hypothesis will be discussed. (C) 2010 Elsevier Inc. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
